Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center

Arthritis and Rheumatism

Volumn 63, Issue 11, 2011, Pages 3547-3551

  Pope, Janet ^a   McBain, Donna ^b   Petrlich, Lisa ^b   Watson, Sharon ^b   Vanderhoek, Louise ^b   De Leon, Faye ^c   Seney, Shannon ^d   Summers, Kelly ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMATINIB; METHOTREXATE; PLACEBO;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEASIBILITY STUDY; FEMALE; FLUID RETENTION; HEALTH ASSESSMENT QUESTIONNAIRE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SKIN BIOPSY; SYSTEMIC SCLEROSIS;

ADULT; AGED; ALOPECIA; ANEMIA; DIARRHEA; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; EDEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PILOT PROJECTS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUESTIONNAIRES; SCLERODERMA, DIFFUSE; TREATMENT OUTCOME;

EID: 80155206225     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30549     Document Type: Article

References (16)

1. Nadashkevic O, Davis P, Fritzler MJ,. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 2004; 10: CR615-21. (Pubitemid 39546036)
2. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5. (Pubitemid 18073738)
3. Distler JH, Distler O,. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 2010; 69 Suppl 1: i48-51.
4. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J,. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 109-16. (Pubitemid 38931842)
5. Varga J, Pasche B,. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-6.
6. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
7. Ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S,. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009; 98: 265-7.
8. Saggar R, Khanna D, Mayes M, Clements P, Maranian P, Furst DE, et al. Open labeled study of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis-associated active interstitial lung disease (SSc-ILD): preliminary results [abstract]. Am J Respir Crit Care Med 2010; 181: A3991.
9. Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 2009; 48: 49-52.
10. Chung L, Fiorentino DF, BenBarak MJ, Adler AS, Mariano MM, Paniagua RT, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009: 60: 584-91.
11. Gordon J, Mersten J, Lyman S, Kloiber SA, Wildman HF, Crow MK, et al. Imatinib mesylate (Gleevec) in the treatment of systemic sclerosis: interim results of a phase IIa, one year, open label clinical trial [abstract]. Arthritis Rheum 2009; 60 Suppl: S226.
12. Spiera RF, Gordon JK, Mersten J, Magro C, Mehta M, Wildman HF, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a one year, phase IIa, single arm, open label clinical trial [abstract]. Arthritis Rheum 2010; 62 Suppl: S920.
13. Distler O, Distler JH, Varga J, Denton CP, Lafyatis RA, Wigley FM, et al. A multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis [abstract]. Arthritis Rheum 2010; 62 Suppl: S233-4.
14. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
15. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45. (Pubitemid 10164318)
16. Pope JE, Shum DT, Gottschalk, R, Stevens A, McManus R,. Increased pigmentation in scleroderma. J Rheumatol 1996; 23: 1912-6. (Pubitemid 26376115)